Qlaris Bio to showcase promising data on QLS-111, a novel glaucoma treatment, at the 2025 World Glaucoma Congress, ...

ADX-2191 is an investigational drug candidate from Aldeyra, for the treatment of primary vitreoretinal lymphoma (PVRL), a ...

New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients ...

FYB203 has been approved by the US FDA and UK Medicines and Healthcare products Regulatory Agency for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema, ...

ST-100 shows promise as a fast-acting treatment for dry eye disease, offering rapid relief and unique collagen repair ...

ForSight Robotics secures $125M to advance its robotic surgery platform, targeting cataract procedures and additional ...

Danegaptide is an oral therapy for early treatment of non-proliferative diabetic retinopathy (NPDR) and associated edema.

As its director, Manusis outlines the facility’s role in delivering advanced, personalized solutions to improve vision and ...

Patients in Ontario expose illegal user fees for cataract surgeries in private clinics, urging government action to uphold ...

Kira Manusis, MD, is Director of the Center for Refractive Solutions and Co-Director of Cataract Services at NYEE.

From laser vision correction to adjustable lens implants, the Center for Refractive Solutions at New York Eye and Ear Infirmary of Mount Sinai offers advanced options for every stage of life.

Funding will support continued product development, while the board is composed of “global leaders in posterior and anterior ...